RemAb Therapeutics develops synthetic polymeric conjugates that selectively bind to and facilitate the rapid clearance of harmful antibodies from circulation, addressing issues related to infectious diseases, autoimmunity, and blood group incompatibility. This targeted removal technology provides patients with immediate clinical benefits by mitigating adverse immune responses.
Funding
Funding not disclosed
Founders
Product
Problem
Harmful antibodies circulating in the body can cause deleterious immune responses, leading to complications in infectious diseases, autoimmunity, blood group incompatibility, and rejection of gene therapies. Current methods for removing these antibodies are often non-selective or have limited efficacy.
Solution
RemAb Therapeutics develops synthetic polymeric conjugates designed to selectively bind to and facilitate the rapid clearance of specific harmful antibodies from circulation. This Harmful Antibody Removal Technology (HART) platform creates immunocomplexes that are quickly metabolized and excreted, delivering immediate clinical benefits by mitigating adverse immune responses. The technology offers a targeted approach to modulate the human immune response in various contexts, including bacterial infections, allergy and autoimmunity, blood group incompatibility, and gene therapy.
Target Audience
The primary target audience includes patients suffering from infectious diseases, autoimmune disorders, blood group incompatibility issues, and those undergoing gene therapy who experience adverse immune responses.
Features
- Synthetic polymeric conjugates engineered for specific antibody binding
- Rapid formation and clearance of immunocomplexes
- Targeted removal of harmful antibodies without affecting beneficial ones
- Customizable conjugates for a range of therapeutic applications
- Potential for long-lasting therapeutic benefits